Laboratory Corporation of America Holdings (NYSE:LH) Director Dwight Gary Gilliland sold 971 shares of Laboratory Corporation of America Holdings stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $153.52, for a total value of $149,067.92. Following the completion of the transaction, the director now directly owns 3,501 shares in the company, valued at approximately $537,473.52. The sale was disclosed in a document filed with the SEC, which is available at this link.

Laboratory Corporation of America Holdings (NYSE:LH) opened at $153.74 on Friday. The company has a market capitalization of $15.45 billion, a P/E ratio of 16.32, a P/E/G ratio of 1.61 and a beta of 0.87. The company has a quick ratio of 1.75, a current ratio of 1.89 and a debt-to-equity ratio of 1.18.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion during the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.25 EPS. equities analysts expect that Laboratory Corporation of America Holdings will post 9.52 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Laboratory Corporation of America Holdings (LH) Director Sells $149,067.92 in Stock” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/insider-selling-laboratory-corporation-of-america-holdings-lh-director-sells-149067-92-in-stock/1677730.html.

Hedge funds have recently modified their holdings of the stock. Acrospire Investment Management LLC grew its position in Laboratory Corporation of America Holdings by 16.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock worth $109,000 after acquiring an additional 100 shares during the last quarter. Sun Life Financial INC grew its position in shares of Laboratory Corporation of America Holdings by 9,200.0% in the 2nd quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after buying an additional 736 shares during the last quarter. IFP Advisors Inc grew its position in shares of Laboratory Corporation of America Holdings by 83.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after buying an additional 523 shares during the last quarter. Hourglass Capital LLC bought a new stake in shares of Laboratory Corporation of America Holdings in the 2nd quarter valued at about $200,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Laboratory Corporation of America Holdings in the 1st quarter valued at about $208,000. Institutional investors and hedge funds own 93.39% of the company’s stock.

Several equities analysts have weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, September 11th. ValuEngine upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th. Craig Hallum restated a “buy” rating and issued a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $173.00 price target for the company in a report on Thursday, September 21st. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $190.00 price target on shares of Laboratory Corporation of America Holdings in a report on Thursday, October 12th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $169.00.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.